| Business Summary | | L.A.M.
Pharmaceutical,
Corp.
seeks
to
develop,
license,
produce
and
sell
novel
and
proprietary
pharmaceuticals.
L.A.M.
has
a
proprietary
drug
delivery
technology
that
involves
the
use
of
an
original
Ionic
Polymer
Matrix
(IPM)
for
the
purpose
of
delivering,
enhancing
and
sustaining
the
action
of
certain
established
therapeutic
agents.
L.A.M.
has
developed
a
transdermal
(through
the
skin)
IPM
drug
designed
to
be
used
in
topical
form
for
the
relief
of
arthritic
pain
and
pain
caused
by
related
conditions
(L.A.M.'s
Diclofenac-IPM).
L.A.M.'s
Diclofenac-IPM
is
a
therapeutic
preparation
containing
30
mg
(milligrams)
of
diclofenac
per
ml
(milliliter).
This
clear,
aqueous
and
highly
absorbent
gel
is
applied
to
the
skin
adjacent
to
the
affected
area.
Various
uses
for
L.A.M.'s
skin-care
product
include
controlling
body
odors,
relief
of
dryness
and
for
moisturization. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | L.A.M.
Pharmaceutical
Corp
is
engaged
in
the
research
and
development
of
novel,
proprietary,
long
lasting
injectable
drugs
and
delivery
systems
for
transdermal
and
topical
drugs.
For
the
six
months
ended
6/30/01,
revenues
totaled
$300
thousand
vs.
none.
Net
loss
rose
from
$916
thousand
to
$2.6
million.
Revenues
reflect
a
licensing
agreement
with
Ixora
Biomedical
Company,
Inc.
Higher
loss
reflects
the
expenses
related
to
obtaining
the
equity
line
of
credit. | More
from
Market Guide: Significant
Developments |
| | |
| Position | Joseph Slechta, 52 | Pres,
COO, Director | Peter Rothbart, M.D., 61 | Treasurer,
Director | Gary Nath, 54 | Sec.,
Director |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|